On the mechanism of the persistent action of salmeterol: what is the current position?
Author:
- 25 August 2009
- journal article
- editorial
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (1) , 180-182
Abstract
The mechanism of the long duration of action of salmeterol at β2‐adrenoceptors has long been a matter of debate, and is still unresolved. Szczuka and colleagues have both summarized the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Much of the literature data that they have drawn upon appears contradictory, and mathematical models are inevitably flawed by the questionable validity of key values applied to them. Although the issue will undoubtedly eventually be resolved, it will probably require investigators to apply carefully designed studies on simple experimental systems such as isolated membranes or cultured cells. Only then should studies be extended to more complex systems such as isolated preparations of airways smooth muscle, where tissue bulk inevitably presents a complicating factor, particularly where relatively lipophilic compounds are concerned.Keywords
This publication has 10 references indexed in Scilit:
- Molecular mechanisms for the persistent bronchodilatory effect of the β2‐adrenoceptor agonist salmeterolBritish Journal of Pharmacology, 2009
- In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1 H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of ActionThe Journal of Pharmacology and Experimental Therapeutics, 2006
- QSAR and the Rational Design of Long-Acting Dual D2-Receptor/β2-Adrenoceptor AgonistsJournal of Medicinal Chemistry, 2003
- Kinetic Analysis of Drug-Receptor Interactions of Long-Acting β2 Sympathomimetics in Isolated Receptor Membranes: Evidence against Prolonged Effects of Salmeterol and Formoterol on Receptor-Coupled Adenylyl CyclaseThe Journal of Pharmacology and Experimental Therapeutics, 1999
- Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists.1996
- Exosites: their current status, and their relevance to the duration of action of long-acting β2-adrenoceptor agonistsTrends in Pharmacological Sciences, 1996
- Extent of salmeterol‐mediated reassertion of relaxation in guinea‐pig trachea pretreated with aliphatic side chain structural analoguesBritish Journal of Pharmacology, 1996
- Why are long-acting beta-adrenoceptor agonists long-acting?European Respiratory Journal, 1994
- Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers.Molecular Pharmacology, 1992
- The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta‐ adrenoceptor agonists.British Journal of Clinical Pharmacology, 1991